Enobia Raises Series B

Enobia Pharma Inc., a Montreal-based developer of enzyme replacement therapies for the treatment of serious bone diseases, has raised Cdn$40.1 million in Series B funding. OrbiMed Advisors and CTI Life Sciences Fund co-led the deal, and were joined by return backers Fonds de solidarite FTQ, Desjardins Venture Capital, Lothian Partners and T2C2/Bio 2000. Enobia's lead candidate focuses on hypophosphatasia, a severe genetic disorder that affects the ability to mineralize bone. www.enobia.com